Has Gilead Sciences, Inc.'s Star Drug Already Peaked?

Prescriptions of Gilead Sciences' hepatitis C drug Sovaldi peaked, but sales will pick up after the new combination product is approved.

Aug 28, 2014 at 8:00PM

Gilead Sciences' (NASDAQ:GILD) hepatitis C drug scored $3.5 billion in sales in the second quarter, but prescriptions have been falling since before the quarter closed.

First, new prescriptions started to fall in March. And then, as you'd expect, total prescriptions, which includes refills, peaked a couple of months later. There isn't necessarily a direct correlation between prescriptions and sales because we don't know how much the remaining patients are paying for the drug, but it appears as if Sovaldi sales in the third quarter will be lower than in the second quarter.

Sovladi Prescriptions

Source: Bloomberg Intelligence.

Fret not
It's just warehousing.


While prescriptions for Sovaldi have peaked and will decline further, demand for drugs containing Sovaldi will pick up once Gilead's Sovaldi-ledipasvir combination is approved by the Food and Drug Administration later this year.

In fact, that's the reason for the decline in Sovaldi prescriptions. Hepatitis C is a very slow-developing disease. For patients who haven't progressed so far that they're experiencing liver damage, getting treatment now or in six months isn't going to make much of a difference.

We saw this same phenomenon with Vertex Pharmaceuticals' (NASDAQ:VRTX) Incivek. U.S. sales peaked in the fourth quarter of 2011 as doctors anticipated the 2013 approval of Sovaldi, which has better efficacy than Incivek.

The main advantage of Sovaldi-ledipasvir isn't necessarily on the efficacy side, but Sovaldi-ledipasvir can be taken alone, while many hepatitis C patients currently have to take Sovaldi with difficult-to-tolerate injected interferon. Beyond the lack of injections, the all-oral combination is a huge advantage because of the flu-like symptoms that many patients experience with interferon.


Source: Gilead Sciences.

I'm actually rather surprised Sovaldi has done as well as it has; I figured only patients whose disease had substantially advanced since the launch of Incivek would take Sovaldi, and the rest would wait for the all-oral treatment.

Off-label combinations
Part of the better-than-expected sales likely has to do with Johnson & Johnson (NYSE:JNJ) gaining FDA approval for Olysio. The drug can be used in combination with Sovaldi without the need for interferon, although it hasn't been approved for that indication.

Bristol-Myers Squibb's (NYSE:BMY) Daklinza can also be used in combination with Solvaldi and was given a thumbs up by European regulators this week for the combination. In the U.S., Daklinza is up for approval in combination with another Bristol-Myers drug, Sunvepra, but Daklinza could be used off-label with Sovaldi once it's approved here, especially since Daklinza-Sovaldi appears to have better efficacy than Daklinza-Sunvepra.

These combinations have the potential to lower Gilead's sales, assuming Gilead charges more for Sovaldi-ledipasvir than it does for Sovaldi alone. To get around this issue, Gilead could set the price of Sovaldi-ledipasvir at the current cost of Sovaldi plus interferon, and then raise the price of Sovaldi to the same as Sovaldi-ledipasvir, making the use of Sovaldi combined with a drug from a different company more expensive than Sovaldi-ledipasvir.

The next round of warehousing
(NYSE:MRK) is working on an all-oral treatment that could have a shorter treatment time. So is Gilead. If they're successful in the clinic, doctors could stop using Sovaldi-ledipasvir (or combinations of Sovaldi and other drugs) and wait for the approval of the faster-acting combination.

Longer term, we could see another warehousing event as the drugs approach their patent life. If generic drugs are a year away, patients may be willing to wait that long to get reduced co-pays.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information